Ryan M. Kramer
Infectious Disease Research Institute
19 Papers
59 Citations
Ryan M. Kramer is an academic researcher from Infectious Disease Research Institute. The author has contributed to research in topics: Adjuvant & Chemistry. The author has an hindex of 9, co-authored 19 publications.
Chat about Author
Papers
A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.
Jesse H. Erasmus,Amit P. Khandhar,Jeff Guderian,Brian Granger,Jacob Archer,Michelle Archer,Emily Gage,Emily Gage,Jasmine Fuerte-Stone,Elise Larson,Susan Lin,Ryan M. Kramer,Rhea N. Coler,Rhea N. Coler,Christopher B. Fox,Dan T. Stinchcomb,Steven G. Reed,Steven G. Reed,Neal Van Hoeven,Neal Van Hoeven +19 more
TL;DR: A two-vialed approach wherein the delivery formulation, a highly stable nanostructured lipid carrier (NLC), can be manufactured and stockpiled separate from the target RNA, which is admixed prior to administration is shown.
137
Working together: interactions between vaccine antigens and adjuvants
Christopher B. Fox,Ryan M. Kramer,Lucien Barnes,Quinton M. Dowling,Thomas S. Vedvick +4 more
- 01 May 2013
TL;DR: This review focuses on the importance of characterizing antigen–adjuvant interactions by summarizing findings involving widely used adjuvant formulation platforms, such as aluminum salts, emulsions, lipid vesicles, and polymer-based particles.
114
Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization
Mark T. Orr,Ryan M. Kramer,Lucien Barnes,Quinton M. Dowling,Anthony L. Desbien,Elyse A. Beebe,John D. Laurance,Christopher B. Fox,Steven G. Reed,Rhea N. Coler,Thomas S. Vedvick +10 more
TL;DR: The development and characterization of a tuberculosis vaccine comprised of both antigen and adjuvant components that are stable in a single vial at sustained elevated temperatures that retains the ability to elicit both antibody and TH1 responses against the vaccine antigen and protect against experimental challenge with Mycobacterium tuberculosis.
52
Particle Sizing of Nanoparticle Adjuvant Formulations by Dynamic Light Scattering (DLS) and Nanoparticle Tracking Analysis (NTA)
TL;DR: Methods for measuring the particle size and concentration of an oil-in-water nanoemulsion are described.
45
Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate
Mellissa Gomez,Joseph McCollum,Hui Wang,Mani Ordoubadi,Chester Jar,Nicholas B. Carrigy,David Barona,Isobel Tetreau,Michelle Archer,Alana Gerhardt,Chris Press,Christopher B. Fox,Ryan M. Kramer,Reinhard Vehring +13 more
TL;DR: The trehalose-trileucine excipient formulations successfully stabilized the adjuvant system, with evidence indicating retention of the antigen, in an inhalable dry powder format suitable for lung delivery.
45